These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38740663)

  • 1. Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins.
    Aryal B; Lehtimaki M; Rao VA
    Pharm Res; 2024 Jun; 41(6):1217-1232. PubMed ID: 38740663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
    Doshi N; Martin J; Tomlinson A
    Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.
    Doshi N; Ritchie K; Shobha T; Giddings J; Gregoritza K; Taing R; Rumbelow S; Chu J; Tomlinson A; Kannan A; Saggu M; Cai SK; Nicoulin V; Liu W; Russell S; Luis L; Yadav S
    Pharm Res; 2021 Sep; 38(9):1563-1583. PubMed ID: 34495486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.
    Doshi N; Giddings J; Luis L; Wu A; Ritchie K; Liu W; Chan W; Taing R; Chu J; Sreedhara A; Kannan A; Kei P; Shieh I; Graf T; Hu M
    Pharm Res; 2021 Mar; 38(3):531-548. PubMed ID: 33713012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations.
    Doshi N; Demeule B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3792-804. PubMed ID: 26419285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Rapid High-Sensitivity Reversed-Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics.
    Cheng Y; Hu M; Zamiri C; Carcelen T; Demeule B; Tomlinson A; Gu J; Yigzaw Y; Kalo M; Yu XC
    J Pharm Sci; 2019 Sep; 108(9):2880-2886. PubMed ID: 31054888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Super Refined™ Polysorbate 20 With Respect to Polysorbate Degradation, Particle Formation and Protein Stability.
    Doshi N; Fish R; Padilla K; Yadav S
    J Pharm Sci; 2020 Oct; 109(10):2986-2995. PubMed ID: 32679214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradation of Polysorbate 20 by Sialate O-Acetylesterase in Monoclonal Antibody Formulations.
    Zhang S; Xiao H; Li N
    J Pharm Sci; 2021 Dec; 110(12):3866-3873. PubMed ID: 34487744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Fatty Acid Composition in Polysorbate 80 on the Stability of Therapeutic Protein Formulations.
    Pegues MA; Szczepanek K; Sheikh F; Thacker SG; Aryal B; Ghorab MK; Wolfgang S; Donnelly RP; Verthelyi D; Rao VA
    Pharm Res; 2021 Nov; 38(11):1961-1975. PubMed ID: 34845573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring polysorbate hydrolysis in therapeutic proteins using an ultrasensitive extraction-free fatty acid quantitation method.
    Zhang S; Riccardi C; Kamen D; Xiao H; Li N
    Anal Biochem; 2022 Jan; 637():114472. PubMed ID: 34801481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Silicone Oil on Free Fatty Acid Particle Formation due to Polysorbate 20 Degradation.
    Fish R; Lin J; Doshi N
    Pharm Res; 2020 Oct; 37(11):216. PubMed ID: 33029664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of Polysorbates and Alternative Surfactants for Interfacial Stress Protection and Mitigation of Fatty Acid Particle Formation in the Presence of an Esterase.
    Roy I; Wuchner K; Stahl P; Tran T; Yaragudi N
    J Pharm Sci; 2024 Sep; 113(9):2688-2698. PubMed ID: 39009347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymatic degradation pattern of polysorbate 20 impacts interfacial properties of monoclonal antibody formulations.
    Gregoritza K; Theodorou C; Heitz M; Graf T; Germershaus O; Gregoritza M
    Eur J Pharm Biopharm; 2024 Jan; 194():74-84. PubMed ID: 38042510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-in-one stability indicating polysorbate 20 degradation root-cause analytics via UPLC-QDa.
    Carle S; Evers DH; Hagelskamp E; Garidel P; Buske J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jan; 1232():123955. PubMed ID: 38128165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the polysorbate degradation fingerprints and kinetics of lipases - how the activity of polysorbate degrading hydrolases is influenced by the assay and assay conditions.
    Glücklich N; Carle S; Buske J; Mäder K; Garidel P
    Eur J Pharm Sci; 2021 Nov; 166():105980. PubMed ID: 34419573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
    Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
    J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
    Diederichs T; Mittag JJ; Humphrey J; Voss S; Carle S; Buske J; Garidel P
    Int J Pharm; 2023 Mar; 635():122660. PubMed ID: 36740078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Protein Particle Formation in IgG1 mAbs Formulated with PS20 Vs. PS80 When Subjected to Interfacial Dilatational Stress.
    Vaclaw C; Merritt K; Griffin VP; Whitaker N; Gokhale M; Volkin DB; Ogunyankin MO; Dhar P
    AAPS PharmSciTech; 2023 Apr; 24(5):104. PubMed ID: 37081185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.
    Zhang J; He J; Smith KJ
    J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.